Cardiomyopathy cost-effectiveness of therapy: Difference between revisions
Lina Yaqoub (talk | contribs) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
{{CMG}}; {{AE}} {{EdzelCo}} | |||
The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually. | The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually. | ||
Latest revision as of 03:31, 27 October 2023
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy cost-effectiveness of therapy |
|
Risk calculators and risk factors for Cardiomyopathy cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD[2]
The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually.
References
Template:WH Template:WS Template:Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu